argenx enters new territory
Netherlands’ based argenx SE is to pay up to $1.15 billion to take full control of a US biotech company and expand its immunology platform to include macrocyclic peptides. The target company, Unnatural Products Inc (UNP), has a preclinical portfolio and is located in Santa Cruz, California. The deal, which follows earlier collaboration and financing agreements, was announced on 9 November.
